Pathophysiology of Gout.

Urate gout hyperuricemia monosodium urate

Journal

Seminars in nephrology
ISSN: 1558-4488
Titre abrégé: Semin Nephrol
Pays: United States
ID NLM: 8110298

Informations de publication

Date de publication:
11 2020
Historique:
entrez: 8 3 2021
pubmed: 9 3 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Multiple interacting checkpoints are involved in the pathophysiology of gout. Hyperuricemia is the key risk factor for gout and is considered a prerequisite for monosodium urate (MSU) crystal formation. Urate underexcretion through renal and gut mechanisms is the major mechanism for hyperuricemia in most people. Multiple genetic, environmental, and metabolic factors are associated with serum urate and alter urate transport or synthesis. Urate supersaturation is the most important factor for MSU crystal formation, and other factors such as temperature, pH, and connective tissue components also play a role. The nucleotide-binding oligomerization domain leucine-rich repeats and pyrin domain-containing protein 3 inflammasome plays a pivotal role in the inflammatory response to MSU crystals, and interleukin 1β is the key cytokine mediating the inflammatory cascade. Variations in the regulatory mechanisms of this inflammatory response may affect an individual's susceptibility to developing gout. Tophus formation is the cardinal feature of advanced gout, and both MSU crystals and the inflammatory tissue component of the tophus contribute to the development of structural joint damage owing to gout. In this article, we review the pathophysiologic mechanisms of hyperuricemia, MSU crystal formation and the associated inflammatory response, tophus formation, and structural joint damage in gout.

Identifiants

pubmed: 33678310
pii: S0270-9295(20)30135-2
doi: 10.1016/j.semnephrol.2020.12.001
pii:
doi:

Substances chimiques

Cytokines 0
Uric Acid 268B43MJ25

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

550-563

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Ravi K Narang (RK)

Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Nicola Dalbeth (N)

Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. Electronic address: n.dalbeth@auckland.ac.nz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH